

**THE UNIVERSITY OF ALABAMA AT BIRMINGHAM  
SCHOOL OF MEDICINE  
FACULTY CURRICULUM VITAE**

**PERSONAL INFORMATION**

**Name:** Larry Wayne Moreland, MD

**Citizenship:** U.S.A.

**Foreign Language(s):** None

**Social Security Number:** 232-96-5656

**Home Address:** 2203 Old South Trace  
Birmingham, AL 35216

**Phone:** (205) 979-1310

**RANK/TITLE**

- Associate Professor of Medicine
- Director, Arthritis Clinical Intervention Research Program
- Associate Scientist, Multipurpose Arthritis Center
- Senior Scientist, Center for Aging

**DEPARTMENT** Department of Medicine

**Business Address:** The University of Alabama at Birmingham  
068 Spain Rehabilitation Center  
Birmingham, AL 35294

**Phone:** (205) 934-2130

**Fax:** (205) 975-6257

**Birthdate:** May 15, 1957

**Birthplace:** Oakland, Maryland

**Marital Status:** Married (Susan Marie)

**Children:** Melissa Faye (12/07/87)  
Amanda Joy (08/03/89)  
Megan Marie (08/24/93)

**HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS:**

West Virginia University Hospital, Department of Medicine, Assistant Professor of Medicine,  
Chief Medical Resident (July, 1986-June, 1987)

Associate in Medicine (Fellowship), Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1987-June, 1990)

Instructor in Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1990-June, 1991)

Assistant Professor of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1991-September, 1994)

Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (October, 1994-Present)

#### **PROFESSIONAL CONSULTANTSHIPS:**

National Scleroderma Clinical Trials Consortium (1990-present)

RW Johnson Pharmaceutical Research Institute; cdr OKT<sub>4a</sub> Advisory Board, February 1, 1993

Roche Laboratories; Humanized Anti-Tac Advisory Board Meeting, March 1, 1993

RW Johnson Pharmaceutical Research Institute; Tepoxalin Advisory Board Meeting, March 4-6, 1994

Site Visit; Duke University, General Clinical Research Clinic, NIH, September 8, 9, 1994

Alexion Pharmaceuticals, July 29, 1994

Marion Merrill Dowe, December 5, 1994

Gene Medicine, Inc. (Consultant)

Cellpro Autoimmune Advisory Board Meeting, January, 1995

#### **EDUCATION:**

<b>Institution</b>	<b>Degree</b>	<b>Year</b>
High School Union High School Mt. Storm, West Virginia (Valedictorian)		1971-1975
Undergraduate West Liberty State College West Liberty, West Virginia (Highest Honors)	B.S.	1975-1979
Medical School West Virginia University Morgantown, West Virginia	M.D.	1979-1983

Internship  
West Virginia University Medical Center  
Morgantown, West Virginia  
Internal Medicine  
(Dr. Robert Waldman) 1983-1984

Residency  
West Virginia University Medical Center  
Morgantown, West Virginia  
Internal Medicine  
(Dr. Robert Waldman) 1984-1986

Chief Medical Resident  
West Virginia University Medical Center  
Morgantown, West Virginia  
Internal Medicine  
(Dr. Stanley Shane) 1986-1987

Fellowship  
The University of Alabama at Birmingham  
Division of Clinical Immunology & Rheumatology  
Birmingham, Alabama  
(Dr. William J. Koopman) 1987-1990

**MILITARY SERVICE:** None

**LICENSURE:** Alabama #13197

**BOARD CERTIFICATION:**

Diplomat of the National Board of Medical Examiners, July, 1984

Diplomat of the American Board of Internal Medicine; Internal Medicine, September, 1987

Diplomat of the American Board of Internal Medicine; Rheumatology, November, 1990

**ACADEMIC APPOINTMENTS:**

Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (October, 1994-Present)

Assistant Professor of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1991-September, 1994)

Instructor in Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1990-June, 1991)

Associate in Medicine (Fellowship), Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama (July, 1987-June, 1990)

West Virginia University Hospital, Department of Medicine, Assistant Professor of Medicine,  
Chief Medical Resident (July, 1986-June, 1987)

**AWARDS/HONORS:**

Scholarship in Mathematics - West Liberty State College

West Liberty State College School of Natural Sciences and Mathematics Department Achievement  
Award, 1978 and 1979

Chi Beta Phi - National Scientific Honorary Fraternity

Graduated from West Liberty State College with Highest Honors

Medical Group Practice, Intern Award for Patient Care, West Virginia University Medical  
Center, 1984

Pfizer Laboratories Arthritis Research Award, 1989-1990; Fellowship Trainee Award

American Federation for Clinical Research (AFCR) Trainee Travel Award to Seattle - May, 1991

Southern Society for Clinical Investigation, February, 1994

Howard & Martha Holley Symposium Research Prize in Rheumatology, May, 1994

**PROFESSIONAL SOCIETIES:**

American Medical Association

American College of Physicians (ACP); Fellow of ACP (FACP), July, 1992

American College of Rheumatology

American Federation for Clinical Research

American Association for the Advancement of Science

Alabama Society for Rheumatic Diseases (Treasurer; 1988-1989)

(Secretary; 1989-1990)

(Vice-president; 1990-1991)

(President; 1991-1992)

Southern Society for Clinical Investigation

**MEMBERSHIPS:**

Fellow, American College of Physicians

American College of Rheumatology

American Federation for Clinical Research

American Medical Association

International Editorial Committee of the Colombian Journal of Rheumatology

**COUNCILS AND COMMITTEES:**

CPR Committee, West Virginia University Hospital (1984-1986)

Medical Student Curriculum Committee, Department of Medicine, West Virginia University Hospital (1985-1986) and (1986-1987)

Housestaff Selection Committee, Department of Medicine, West Virginia University Hospital (1985-1986) and (1986-1987)

Inpatient Committee, Department of Medicine, West Virginia University Hospital (1985-1986) and Chairman (1986-1987)

Medical Board (Member), West Virginia University Hospital (1986-1987)

Patient Care Review Committee; Quality Assurance Subcommittee, West Virginia University Hospital (1986-1987)

Scheduling, Appointments and Registration Committee; The University of Alabama at Birmingham (July, 1990-December, 1991)

Intern Selection Committee; Department of Medicine, The University of Alabama at Birmingham (September, 1990-May, 1992)

Scientific Advisory Committee of the General Clinical Research Center, The University of Alabama at Birmingham (September, 1991-present)

American College of Rheumatology; Committee for Clinical Trials Using Office-based Arthroscopy (May, 1992-July, 1993)

American College of Rheumatology; Committee to Evaluate and Develop Scoring Systems for Intraarticular Pathology Using Office-based Arthroscopy (May, 1992-October, 1994)

Cost Containment Committee; The University of Alabama Hospital (October, 1992-present)

American College of Rheumatology; Professionals Meetings Committee (July, 1994-present)

Quality Assurance Committee, Department of Medicine (July, 1994-present)

The Kirklin Clinic Research Committee, March, 1995 - present

American College of Rheumatology Abstract Selection Subcommittee: Rheumatoid arthritis: treatment, 1995

#### **UNIVERSITY ACTIVITIES:**

##### Clinical/Administrative Responsibilities:

Director, Arthritis Clinical Intervention Research Program, Division of Clinical Immunology and Rheumatology (April, 1989-present)

Director, Spain Rehabilitation Rheumatology Inpatient Service (July, 1990-July, 1994)

Director, Scleroderma Clinic, Division of Clinical Immunology and Rheumatology (August, 1991-present)

Outpatient Arthroscopy, Division of Clinical Immunology and Rheumatology (January, 1990-present)

Director, Rheumatology-Orthopedics Weekly Conference, Spain Rehabilitation Rheumatology Service (July, 1990-December, 1993)

Associate Scientist, Multipurpose Arthritis Center, The University of Alabama at Birmingham (July, 1990-October, 1994)

Scientist, Multipurpose Arthritis Center, The University of Alabama at Birmingham (October, 1994-present)

Senior Scientist, Center for Aging, The University of Alabama at Birmingham (April, 1993-present)

Teaching Responsibilities:

Fellows:

- Weekly Rheumatology/Orthopaedics Conference, Director (July, 1990 - December, 1993)
- Rheumatology Weekly Cooper Green Hospital Clinic 1990 - 1995 ( 2 months/year)
- Rheumatology Fellows Weekly Clinic, The Kirklin Clinic 1993 - 1995 (2 months/year)
- Outpatient Arthroscopy (January, 1990 -present)
- Inpatient Wards/Consult Service (See Residents below)

Residents:

- Ward Rounds (Inpatient and Consult Service) 1989 - 1990 (2 months), 1990 - 1991 (4 months), 1991 - 1992 (3 months), 1992 - 1993 (3 months), 1993 - 1994 (3 months), 1994 - 1995 (2 months)
- Rheumatology Weekly Cooper Green Hospital Clinic 1990 - 1995 (2 months/year)

Medical Students:

- Physical Diagnosis Instructor (Year II Medical Students) 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995
- Correlative Pathology Lectures (Year II Medical Students) 1990, 1991, 1992, 1993, 1994
- Ward Rounds (Fourth year students) 1989 - 1990 (2 months), 1990 - 1991 (4 months), 1991 - 1992 (3 months), 1992 - 1993 (3 months), 1993 - 1994 (3 months), 1994 - 1995 (2 months)
- Summer Clerkship (1991) - David Brown (Year II Medical Student)

Mentor for Fellows: Clinical Intervention Research Program, Division of Clinical Immunology and Rheumatology

- Win Pratt, MD (2nd and 3rd years of fellowship); 1991-1993

- William Sullivan, MD (2nd year of fellowship); 1992-1993
- Gene Watterson, MD (2nd year of fellowship); 1993-present
- Gary Margolies, MD (2nd year of fellowship); 1993-1994
- Jaime Calvo-Alen, MD (Hospital Universitario "Marquesde Valdecilla" Instituto Nacional de La Salud)  
1 year preceptor in Arthroscopy; August, 1993-August, 1994
- Eric Rich, MD (Montreal, Canada) (2 year preceptor in Clinical Research);  
October, 1994-present

Patient Care Responsibilities:

- Inpatient Rheumatology Ward Attending/Consult Service:  
1989-1990, (2 months); 1990-1991, (4 months); 1991-1992, (3 months);  
1992-1993, (3 months); 1993-1994, (3 months); 1994-1995 (2 months)
- Outpatient Clinics:  
The Kirklin Clinic (TKC) - 2-½ days/week  
Bessemer Clinic (2½ days/month)  
Arthroscopies - ½ day/week  
Supervising Fellows - TKC (2 months/year)  
Supervising Fellows - Cooper Green Clinic (2 months/year)  
Director, Scleroderma Clinic - ½ day/week
- Clinical Intervention Research Program; (April, 1989-present)  
Supervise 3 clinical coordinators, 2 administrative assistants and 1 data coordinator
- Director, Spain Rehabilitation Rheumatology Inpatient Service  
(July, 1990-July, 1994)

**RESEARCH INTERESTS:**

- Etiopathogenesis of Rheumatoid Arthritis
- New Therapies for Rheumatoid Arthritis
- New Therapies for Osteoarthritis
- Scleroderma
- Arthroscopy
- Osteoporosis

**EXTERNAL FUNDING:**

- N.I.H.: Clinical Associate Physician (CAP) Award via General Clinical Research Center (07/01/93-07/30/96)
- N.I.H.: Role of Mycoplasma and Chlamydiae in Rheumatoid Arthritis (Gail Cassell, M.D.; P.I.) (01/15/94-12/31/99)
- American College of Rheumatology: Outpatient Arthroscopy for Early Knee Osteoarthritis (01/01/94-12/31/94)
- Pharmaceutical Support for Clinical Trials: Immunex, Inc.; Centocor, Inc.; R.W. Johnson Pharmaceutical Research Institute; Anergen, Inc.; Hoerscht; Sanofi-Winthrop; Proctor and Gamble, Inc.; Searle, Inc.; Monsanto, Inc.; Schering-Plough; Wyeth-Ayerst; MGI Pharma, Inc.
- Pending: R0-1: Mechanisms of Tissue Injury in Rheumatoid Arthritis (Larry Moreland, MD; P.I.)

- Pending: R0-1: Multicenter Trial, Effects of Doxycycline on Osteoarthritis Progression (Ken Brandt, MD, P.I.; University of Indiana)

#### **EDITORIAL BOARD MEMBERSHIPS:**

##### Reviewed Manuscripts for the Following Journals:

The American Journal of Medicine  
The Journal of Clinical Investigation  
The American Journal of the Medical Sciences  
Chest  
Arthritis and Rheumatism  
Arthritis Care and Research  
The Western Journal of Medicine  
Southern Medical Journal

##### Member of Editorial Boards

International Editorial Committee of the Colombian Journal of Rheumatology

#### **MAJOR LECTURES AND VISITING PROFESSORSHIPS:**

University of Tennessee-Memphis, Rheumatology Grand Rounds, August 29, 1989; "Collagen Type II As A Marker of Cartilage Destruction"

Mercy Hospital and Medical Center, San Diego, CA, Medicine Grand Rounds, July 17, 1990; "Current and New Therapies for Rheumatoid Arthritis"

United Scleroderma Foundation Annual National Meeting, Huntsville, Alabama, August 18, 1990; "Bone, Joint, Muscle and Nervous System Involvement in Scleroderma"

35th Greenville Post Graduate Seminar, Greenville, South Carolina, March 26-28, 1991; "Rheumatoid Arthritis - New Advances in Understanding the Disease and Its Treatment"

European Concerted Action on Immunopathogenesis and Immunotherapy of Rheumatoid Arthritis (2nd Annual Meeting), Schlob Elmau, Bavarian Alps, April 21-24, 1991; "Chimeric anti-CD<sub>4</sub> in treating Rheumatoid Arthritis"

University of Alabama in Huntsville, Ninth Annual Review of Modern Therapeutics, Huntsville, Alabama, April 12-13, 1991; "Current Perspectives in the Treatment of Rheumatoid Arthritis"

Metropolitan Atlanta Rheumatology Society (MARS) Monthly Meeting, June 20, 1991; "New Approaches in the Treatment and Monitoring of Disease Activity in Rheumatoid Arthritis"

University of Tennessee-Memphis, Rheumatology Grand Rounds, August 27, 1991; "Arthroscopy for the Rheumatologist"

Washington University, Rheumatology Grand Rounds, September 19, 1991; "Anti-CD<sub>4</sub> Therapy for Rheumatoid Arthritis"



St. Louis University, Rheumatology Grand Rounds, September 20, 1991; "Anti-CD<sub>4</sub> Therapy for Rheumatoid Arthritis"

Boston University, Rheumatology Grand Rounds, November 15, 1991; "Chimeric Anti-CD<sub>4</sub> Antibodies for Treatment of Refractory Rheumatoid Arthritis"

American College of Physicians, Scleroderma Study Section Panel Discussion: Potential New Therapies for Scleroderma, November 18, 1991; National American College of Rheumatology Meeting, Boston, MA

Northwestern University, Rheumatology Grand Rounds, February 3, 1992; "Biologic Agents in Treatment of Refractory Rheumatoid Arthritis"

Loyolla University, Rheumatology Grand Rounds, February 4, 1992; "Biologic Agents in Treatment of Refractory Rheumatoid Arthritis"

The University of Alabama at Birmingham, Medicine Grand Rounds, February 13, 1992; "Biologic Agents in Treating Autoimmune Diseases"

36th Greenville Post Graduate Seminar, Greenville, South Carolina, March 24, 1992; "Differential Diagnosis of Joint Pains"

Ohio State University, Medicine Grand Rounds, April 30, 1992; "Biologic Agents in Treating Autoimmune Diseases"

Ohio State University, Rheumatology Grand Rounds, May 1, 1992; "Arthroscopy - Its Role in Rheumatology"

West Virginia University, Medicine Grand Rounds, May 3, 1992; "Biologic Agents in Treating Autoimmune Diseases"

Jacksonville Rheumatology Society Meeting, Jacksonville, Florida, May 21, 1992; "Potential of Biologic Agents in Treating Autoimmune Diseases"

Indiana University, Rheumatology Grand Rounds, September 8, 1992; "Arthroscopy for the Rheumatologists"

Indiana University, Department of Anatomy Seminar, September 9, 1992; "Digital Subtraction Radiography"

South Carolina Rheumatism Society Annual Meeting, Ashville, North Carolina, September 19-20, 1992; "Effects of NSAID's on Bone" and "New Treatments for Rheumatoid Arthritis"

University of Wisconsin, Madison, WI; Focus on Rheumatology, November, 1992; "Biologic Agents for the Treatment of Rheumatoid Arthritis"

Instructor for American College of Rheumatology Sponsored Office-based Arthroscopy courses; Chicago, June, 1992; Philadelphia, July, 1992; Palo Alto, August, 1992; Atlanta, May, 1993; Boston, July, 1993

American College of Rheumatology National Meeting, Atlanta, GA, Arthroscopy Study Group, October, 1992; "Office-based Arthroscopy - Opportunities for Research"

The Second International Symposium on the Immunotherapy of the Rheumatic Diseases, Brighton, England, April 1-4, 1993; "Experience With a Chimeric Monoclonal Anti-CD<sub>4</sub> Antibody in the Treatment of Refractory Rheumatoid Arthritis"

University of Pennsylvania, Eighth Annual Clinical Update in Rheumatology, September 21, 1993; "New Strategies with Biologic Agents to Inhibit T-Cell Function in Rheumatoid Arthritis" and "Arthroscopy: Evolution of Its Use by Rheumatologists in Investigation and Clinical Practice"

West Virginia University, Third Annual N. LeRoy Lapp Internal Medicine Teaching Days, October 21-23, 1993; "Why Consider Immunomodulating Agents in Treating Rheumatoid Arthritis"

Fourth Columbian Congress of Rheumatology, II International Symposium, Bogota, Columbia, December 3-6, 1993; "Etiopathogenesis of Rheumatoid Arthritis" and "Potential of Biologic Agents in Treating Autoimmune Diseases"

The Third Annual International Business Communications on Rheumatoid Arthritis, Boston, MA, December 13-14, 1993; "Experience with Chimeric Anti-CD<sub>4</sub> in the Treatment of Rheumatoid Arthritis"

Department of Medicine Research Conference, The University of Alabama at Birmingham, February 28, 1994; "Biologic Agents for Treatment of Rheumatoid Arthritis"

Howard & Martha Holley Symposium Research Prize in Rheumatology: New Horizons in the Treatment of Rheumatoid Disease, Southeastern Regional American College of Rheumatology Meeting, Orlando, Florida, May 13-15, 1994, "Biologic Agents for Treatment of Autoimmune Diseases"

Brigham & Women's Hospital, Harvard University Rheumatology Grand Rounds, May 31, 1994; "Biologic Agents for Treating Rheumatoid Arthritis"

12th Annual Rheumatology on the Beach, Sandestin, FL, September 22-25, 1994; "Cytokine Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis"

American College of Rheumatology; 58th Annual National Meeting, Minneapolis, MN, October, 1994; Biologics Study Group: "Approach to Cytokine Regulation in Rheumatoid Disease"

Fourth Annual International Business Communications Symposium on Rheumatoid Arthritis, Washington, DC, December, 1994; "Potential New Therapies for Rheumatoid Arthritis: Anti-CD<sub>4</sub>, TNFR: Fc Receptor"

Second Annual International Business Communications Symposium on Osteoarthritis, Washington, D.C., November, 1994; "Hylan G-F20 in Treating Osteoarthritis"

Biologic Agents in Autoimmune Disease IV, San Francisco, CA, March 2, 1995: "Results of a Phase I Trial Using Recombinant Soluble Tumor Necrosis Factor Receptor (p80) Fusion Protein (STNF-R:Fc)"

National American College of Physicians Meeting: "New Therapies: Collagen Vascular Disease"; Atlanta, GA, March 19, 1995

Central Regional American College of Rheumatology Meeting, Chicago, IL: "Biologic Therapies: Fact or Fiction"; March 29, 1995

5th Annual Cleveland Clinic Review of Rheumatic Disease, Cleveland, OH: "Biologic Agents for Treatment of Rheumatic Diseases: Current Status"; May 3, 1995

3rd International Symposium on Immunotherapy of Rheumatic Diseases, Cyrus, May 11-15, 1995; Use of Soluble TNF Receptor Fusion Protein and Soluble Interleukin-1 Receptor for Treatment of Rheumatoid Arthritis

Third International Workshop on Synovitis, Leiden, June 15-17, 1995: "Immunohistochemical Features of Early Rheumatoid Arthritis Synovitis"

#### MANUSCRIPTS:

##### Published Manuscripts:

1. **Moreland LW**, McKenzie R, Brick J: Temporal arteritis presenting with diplopia. *West Virginia Medical Journal* 82:481-482, 1986
2. **Moreland LW**, Kovach RF, Brick JE, DiBartolomeo AG, Mullins MC: Acute febrile neutrophilic dermatosis (Sweet's syndrome): A review of the literature with emphasis on musculoskeletal manifestations. *Semin Arthritis Rheum* 17:143-155, 1988
3. **Moreland LW**, Corey J, McKenzie R: Ludwig's angina: report of a case and review of the literature. *Arch Intern Med* 148:461-466, 1988
4. **Moreland LW**, DiBartolomeo A, Brick J: Rheumatoid vasculitis with intrarenal aneurysm formation. *J Rheumatol* 15:845-849, 1988
5. Bathon JM, **Moreland LW**, DiBartolomeo AG: Inflammatory central nervous system involvement in rheumatoid arthritis. *Semin Arthritis Rheum* 18:258-266, 1989
6. Brick JE, **Moreland LW**, Al-Kawas F, Chang WWL, Layne RD, DiBartolomeo AG: Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid arthritis. *Semin Arthritis Rheum* 19:31-44, 1989
7. Brick JE, **Moreland LW**, DiBartolomeo AG: Methotrexate therapy in rheumatoid arthritis: results after eight years of experience at West Virginia University. *West Virginia Medical Journal* 85:50-53, 1989
8. **Moreland LW**, López-Mendéz A, Alarcón, GS: Spinal stenosis: A comprehensive review of the literature. *Semin Arthritis Rheum* 19:127-149, 1989
9. **Moreland LW**, Koopman WJ: Viral arthritis in man. *Curr Opin Rheumatol* 1:185-193, 1989
10. Chatham W, Williams G, **Moreland L**, Parker JW, Ross C, Alarcón GS: Intraarticular injections: Should we rest the joints? *Arthritis Care Res* 2:70-74, 1989
11. **Moreland LW**, Stewart T, Gay RE, Huang G, McGee N, Gay S: Immunohistological demonstration of collagen type II in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. *Arthritis Rheum* 32:1458-1464, 1989

12. **Moreland LW, Alarcón GS:** Evaluation of patients with progressive systemic sclerosis (letter). *Arthritis Rheum* 32:1631-1632, 1989
13. **Moreland LW, Ball GV:** Cutaneous polyarteritis nodosa. *Am J Med* 88:426-430, 1990
14. **Ambrose RF, Moreland LW, Kendall LG, Brown S, Koopman WJ, Alarcón GS:** Achieving consensus for an algorithm for the treatment of rheumatoid arthritis with methotrexate. *Arthritis Care Res* 3:53-57, 1990
15. **Moreland LW, Daniel WW, Alarcón GS:** The value of the Norgaard view in the evaluation of erosive arthritis. *J Rheumatol* 17:614-617, 1990
16. **Moreland LW, Chatham WW, Alarcón GS:** Intraarticular injections (letter). *Arthritis Care Res* 3:104-105, 1990
17. **Moreland LW, Ball GV:** Colchicine and gout. *Arthritis Rheum* 34:782-786, 1991
18. **Antonelli MAS, Moreland LW, Brick JE:** Herpes zoster in rheumatoid arthritis patients treated with weekly, low dose methotrexate. *Am J Med* 90:295-298, 1991
19. **Austin JS, Ambrose RF, Young PK, Moreland LW, Saway PA, Alarcón GS:** Rheumatoid arthritis patients and clinical drug trials: a case control study. *Arthritis Care Res* 4:22-26, 1991
20. **Moreland LW, Gay RE, Gay S:** Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. *Clin Immuno Immunopathol* 60:412-418, 1991
21. **Moreland LW, Koopman WJ:** Infection as a cause of arthritis. *Curr Opin Rheumatol* 3:639-649, 1991
22. **Gay S, Trabandt A, Moreland L, Gay RE:** Growth factors, extracellular matrix and oncogenes in scleroderma. *Arthritis Rheum* 35:304-310, 1992
23. **Moreland LW, Reddy MS, Koopman WJ, Webber R, Alarcón GS, Jeffcoat MK:** Digital subtraction radiography for the assessment of bone changes in rheumatoid arthritis. *J Rheumatol* 19:1697-1703, 1992
24. **Moreland LW, Koopman WJ:** Infection as a cause of musculoskeletal diseases: reactive arthritis and rheumatic fever. *Curr Opin Rheumatol* 4:534-542, 1992
25. **Moreland LW, Goldsmith KT, Russell WJ, Young KR Jr, Garver RI Jr:** Transforming growth factor  $\beta$  within fibrotic scleroderma lungs. *Am J Med* 93:628-636, 1992
26. **Moreland LW, Bucy RP, Pratt PW, Tilden A, LoBuglio AF, Khazaeli M, Everson M, Sanders ME, Allen E, Kilgariff C, Khrayeb I, Daddona P, Koopman WJ:** Use of a chimeric monoclonal anti-CD<sub>4</sub> antibody in patients with refractory rheumatoid arthritis. *Arthritis Rheum* 36:307-318, 1993
27. **Stransky G, Vernon J, Aicher W, Moreland LW, Gay RE, Gay S:** Virus-like particles in synovial fluids from patients with rheumatoid arthritis. *Br J Rheumatol* 32:1044-1048, 1993
28. **Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilapoulas G, Stromatt SC:** Misoprostol for the prevention of nonsteroidal anti-inflammatory drug-induced duodenal ulcer: a double-blind, placebo-controlled study. *Ann Int Med* 119:257-262, 1993
29. **Moreland LW, Heck LW, Sullivan W, Pratt PW, Koopman WJ:** New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. *Am J Med Sci* 305:40-51, 1993
30. **Moreland LW, Sanders M, Pratt W, Koopman WJ:** Experience with a chimeric monoclonal anti-CD<sub>4</sub> antibody in the treatment of refractory rheumatoid arthritis. *Clin and Experimental Rheumatology* 11:S153-S159, 1993

31. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman A, Allegan N, Varga J, Massa M, Wigley FM, Ingenito F, Weisman M, Needleman B, Martin RW, McCloskey D, **Moreland LW**, Mayes M, Lally EV, Uname M, Collier DH, Weiner S, Weinstein A, Medsger TA, Jr, Andrews B, Dixon M, Furst DE: Skin thickness score in systemic sclerosis (SSC): An assessment of interobserver variability in three independent studies. *J Rheumatol* 20:1892-1896, 1993
32. Jeffcoat MK, Reddy MS, **Moreland LW**, Koopman WJ: Effects of nonsteroidal anti-inflammatory drugs on bone loss in chronic inflammatory disease. *Annals NY Acad Sci* 696:292-302, 1993
33. Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, Weisman MH, Lee P, **Moreland LW**, Neumer R, Gall EP, Clements PC, Spindler J, Lally EV: Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheumatol* 21:105-110, 1994
34. **Moreland LW**, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ: Treatment of refractory rheumatoid arthritis with a chimeric anti-CD<sub>4</sub> monoclonal antibody: Longterm follow-up of CD<sub>4</sub><sup>+</sup>T cell counts. *Arthritis Rheum* 37:834-838, 1994
35. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, Wigley F, Medsger T Jr, Steen V, **Moreland L**, Dixon M, Massa M, Lally E, McCloskey D, Varga J, Ingenito F, Furst D: Inter- and intra-observer variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis (SSc). *J Rheumatol* (in press)
36. **Moreland LW**, Heck LW Jr., Koopman WJ, Saway PA, Adamson TC, Fronck Z, O'Connor RD, Morgan EE, Diveley JP, Chieffo NM, Freeman TD, Carlo DJ, Brostoff SW: V $\beta$ 17 receptor peptide vaccine: results of a phase I dose finding study in patients with rheumatoid arthritis. *Annals NY Acad Sci*
37. **Moreland LW**, Calvo-Alén J; Koopman WJ: Synovial biopsy of the knee joint under direct visualization by needle arthroscopy. *J Clinical Rheumatology* 1:103-108, 1995
38. **Moreland LW**, Sewell KL, Trentham DE, Sullivan WF, Shmerling RH, Bucy RP, Parker KC, Swartz WG, Woodworth TG, Koopman WJ: Diphtheria-interleukin-2 fusion toxin (DAB<sub>486</sub> IL-2) in patients with refractory rheumatoid arthritis: Results of a double-blind placebo controlled trial. *Arthritis Rheum* (in press)
39. **Moreland LW**, Bucy RP, Koopman WJ: Reconstitution of CD<sub>4</sub><sup>+</sup> T-lymphocytes in patients with rheumatoid arthritis treated with a depleting anti-CD<sub>4</sub> monoclonal antibody. *N Eng J Med* (in press)
40. **Moreland LW**: Combining traditional anti-arthritis drugs with biologic agents in treating rheumatoid arthritis. Submitted
41. **Moreland LW**, Koopman WJ: Results of a Phase I trial using recombinant soluble tumor necrosis factor receptor (p80) fusion protein (sTNF-R:Fc) to treat rheumatoid arthritis (in press)
42. **Moreland LW**: Spinal Stenosis Bulletin on the Rheumatic Diseases (in press)
43. **Moreland LW**, Koopman WJ: Experimental biologic treatments of rheumatoid arthritis. *Cliniquide to Rheumatology* (in press)
44. **Moreland LW**, Pratt PW, Mayes M, Postlethwaits A, Weisman M, Schnitzer T, Lightfoot R, Calabrese L, Woody JN, Koopman WJ: Double-blind, placebo controlled multicenter trial using chimeric monoclonal anti-CD<sub>4</sub> antibody in rheumatoid arthritis patients receiving concomitant methotrexate. *Arthritis Rheum* (in press)

# **Manuscripts submitted but not yet accepted:**

1. Jacobs JP, Daenzer CL, Oleen-Burkey M, Perry KT, Lisse JR, **Moreland LW**, Osborn TG, Prete PE, Wigley FM: Comparison of flurbiprofen with diclofenac for the treatment of rheumatoid arthritis. Submitted
2. Alarcón GS, Moreland LW, Jaffee K, Phillips RM, Bocanegro T, Russell IJ, for the Methotrexate Surgery Study Group: The use of methotrexate peri-operatively in patients with rheumatoid arthritis undergoing major joint replacement surgery. Submitted
3. **Moreland LW**, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O'Connor RD, Morgan EE, Diveley JD, Richieri SP, Carlo DJ, Porostoff SW: V $\beta$ 17 T-cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. Submitted

# **Other publications:**

1. **Moreland L**: "Acne and Arthritis", December, 1987. Southern Medical Association; Dial Access
2. **Moreland LW**: "Nodular panniculitis." November, 1989, Southern Medical Association; Dial Access, updated November, 1991
3. **Moreland LW**: "Musculoskeletal manifestations of pyoderma gangrenosum and acne." November, 1989, Southern Medical Association; Dial Access, updated November, 1991
4. **Moreland LW**: "Multicentric reticulohistocytosis and Sweet's syndrome." November, 1989, Southern Medical Association; Dial Access, updated November, 1991
5. **Moreland LW**: "Musculoskeletal syndromes associated with malignancy." November, 1989, Southern Medical Association; Dial Access, updated November, 1991
6. **Moreland LW**: "Arthropathies associated with endocrine diseases." November, 1989, Southern Medical Association; Dial Access, updated November, 1991
7. **Moreland LW**: "Arthroscopy", November, 1991, Southern Medical Association; Dial Access
8. **Moreland LW**: The evaluation of cartilage and synovial changes in OA of the knee with the treatment of flurbiprofen using an optical catheter system arthroscope. Presented in Sanoma, California symposium on "The effects of flurbiprofen on the immune response." Published in Monograph 1990, 43-46

# **BOOKS:**

## **Book Chapters:**

1. **Moreland LW**: Osteoarthritis, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 593-595
2. **Moreland LW**: Mixed connective tissue disease, overlap syndrome, and antiphospholipid antibody syndrome, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 582-583
3. **Moreland LW**: Nonarticular rheumatism, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 601-602

4. **Moreland LW:** Scleroderma, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 578-581
5. **Moreland LW:** Systemic lupus erythematosus, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 568-573
6. **Moreland LW:** Approach to the patient with musculoskeletal disease, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 560-564
7. **Moreland LW:** Miscellaneous forms of arthritis, In Cecil's Essentials of Medicine. Edited by TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, Jr. Third edition. Philadelphia, WB Saunders, 1993, pp 597-600
8. **Moreland LW, Koopman WJ:** Biological agents as potential new therapies for autoimmune diseases. Primer on the Rheumatic Diseases. Editor, H. Ralph Schumacher, Jr.; Associated editors, John H. Klippel, William J. Koopman; The Arthritis Foundation, 1993, Tenth edition pp 307-310
9. **Watterson G, Moreland LW:** "Osteoarthritis", Women's Medicine Textbook, editor Richard E. Blackwell. In press
10. **Margolies GR, Koopman WJ, Moreland LW:** Treatment of rheumatoid arthritis with soluble tumor necrosis factor receptor. In: Emerging Therapies in Autoimmune Disease. In press
11. **Moreland LW, Koopman WJ:** Chimeric anti-CD<sub>4</sub> antibody as a potential therapeutic agent for rheumatoid arthritis. In: Emerging Therapies in Autoimmune Disease. In press
12. **Heck LW Jr, Moreland LW, Koopman WJ:** T-cell receptor peptide vaccination: studies in rheumatoid arthritis. In: Emerging Therapies in Autoimmune Diseases. In press
13. **Moreland LW, Koopman WJ:** Biologic therapies for autoimmune diseases. In: Arthritis and Allied Conditions, 13th Edition. Editor: William J Koopman. In press
14. **Kalunian KC, Moreland LW, Ike RW:** Arthroscopy. In Arthritis and Allied Conditions, 13<sup>th</sup> Edition. Editor: William J. Koopman. In press

#### Published abstracts:

1. **Moreland LW, Brick JE, Kovach RF, DiBartolomeo AG, Mullins MC:** Musculoskeletal manifestations of acute febrile neutrophilic dermatosis (Sweet's syndrome). Arthritis Rheum (Suppl) 31:R47, 1988
2. **Brick JE, Moreland LW, DiBartolomeo AG:** Outcome analysis of selected methotrexate (MTX) treated rheumatoid arthritis (RA) patients. Arthritis Rheum (Suppl) 31:R36, 1988
3. **Brick JE, Moreland LW, Al-Kawas F, Chang WWL, DiBartolomeo AG:** Prospective analysis of pre and post methotrexate (MTX) liver biopsies (Bx) in rheumatoid arthritis (RA) patients. Arthritis Rheum (Suppl) 31:R41, 1988
4. **Moreland LW, Brick JE, Kovach RF, DiBartolomeo AG, Mullins MC:** Acute febrile neutrophilic dermatosis (Sweet's syndrome): A review of the literature with emphasis on musculoskeletal manifestations. Orthopedics Rheumatology Digest; 6:27-8, 1988
5. **Moreland L, Huang GQ, Gay R, Stewart T, Gay S:** Immunohistological demonstration of collagen type II in synovial fluid phagocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Arthritis Rheum (Suppl) 31:S18, 1988
6. **Brick J, Moreland L, Al-Kawas F, Chang W, DiBartolomeo A:** Prospective analysis of pre and post methotrexate (MTX) liver biopsies (Bx) in rheumatoid arthritis (RA) patients. Arthritis Rheum (Suppl) 31:S29, 1988

7. **Moreland LW**, López-Méndez A, Alarcón GS: Spinal stenosis (SPST) as seen by rheumatologists (R) in a university-based rheumatology practice. *Arthritis Rheum (Suppl)* 32:R27, 1989
8. Stewart TE, Mestecky J, **Moreland LW**, Gay S: Immunoassay for collagen type II (CII) in synovial fluid and serum of patients with erosive joint diseases. *Arthritis Rheum (Suppl)* 32:R57, 1989. *Arthritis Rheum (Suppl)* 32:S8, 1989
9. **Moreland LW**, McGee N, Huang G, Stewart T, Gay S: Immunoelectron microscopy (IEM) of collagen type II (CII) in synovial fluid phagocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. *Arthritis Rheum (Suppl)* 32:R9, 1989
10. Alarcón GS, **Moreland LW**, Ambrose RE, Kendall Jr LG, Brown Jr S: Theory vs practice in the development and validation of a methotrexate (MTX) algorithm (ALGO) for rheumatoid arthritis (RA). *Arthritis Rheum (Suppl)* 32:R66, 1989. *Arthritis Rheum (Suppl)* 32:S62, 1989
11. Chatham WW, Williams GV, **Moreland LW**, Parker JW, Ross C, Alarcón GS: Intraarticular (IA) injections: should we rest the joints (JTS)? *Arthritis Rheum (Suppl)* 32:R67, 1989
12. **Moreland L**, Stewart T, Gay RE, Gay S: Autoantibodies to collagen types I-VI in vasculitis and systemic lupus erythematosus. *Arthritis Rheum (Suppl)* 32:S125, 1989
13. Joy JL, López-Méndez A, **Moreland LW**, Alarcón GS, Oh SH: Electrophysiologic findings in patients with radiologically proven spinal stenosis. *Muscle Nerve*
14. **Moreland LW**, Daniel WW, Alarcón GS: The value of the Norgaard view (NV) in the evaluation of erosive arthritis. *Arthritis Rheum (Suppl)* 33:R19, 1990
15. **Moreland LW**, Huang G, Gay RE, Jones RE, Blackburn WD, Alarcón GS, Gay S: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in scleroderma (SCL) skin. *Arthritis Rheum (Suppl)* 33:R14, 1990; *Arthritis Rheum (Suppl)* 33:S36, 1990
16. Stransky G, **Moreland LW**, Gay RE, Gay S: Virus-like particles (VLP) in synovial fluids from patients with rheumatoid arthritis (RA). *Arthritis Rheum (Suppl)* 33:S143, 1990
17. **Moreland LW**, Ray RE, Gay S: Immunological detection of collagen type II in patients with rheumatoid arthritis and osteoarthritis. *Clinical Research* 38:975A, 1990
18. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Ghrayeb J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Treatment of refractory rheumatoid arthritis (RA) with a chimeric anti-CD<sub>4</sub> monoclonal antibody. *J Cell Biochem (Suppl)* 15E:183, 1991; *Arthritis Rheum (Suppl)* 34:R26, 1991; *Clinical Research* 39:309A, 1991
19. **Moreland LW**, Reddy MS, Koopman WJ, Sawyer MS, Bowden JC, Jeffcoat MK: Detection of erosive changes in rheumatoid arthritis (RA) using digital image subtraction radiography (DISR). *Arthritis Rheum (Suppl)* 34:R26, 1991
20. Pratt PW, **Moreland LW**, Barker JS, Snider AM, Alarcón GS: Routine bacteriologic studies in synovial fluid (SF) from inflamed joints in rheumatoid arthritis (RA) patients: a reassessment. *Arthritis Rheum (Suppl)* 34:R27, 1991
21. Reddy MS, Jeffcoat MK, **Moreland LW**, Koopman WJ, Webber R: Digital subtraction radiography for the assessment of bone change in rheumatoid arthritis (RA). *Arthritis Rheum (suppl)* 34:S63, 1991
22. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Ghrayeb J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Use of a chimeric anti-CD<sub>4</sub> monoclonal antibody in refractory rheumatoid arthritis. *Arthritis Rheum (suppl)* 34:S49, 1991



23. Brown DA, **Moreland LW**, Alarcón GS: Practice variations in the administration of gold salts (GS) for the treatment of rheumatoid arthritis (RA) during a ten year period. *Arthritis Rheum (Suppl)* 35:R10, 1992; *Arthritis Rheum (Suppl)* 35:S203, 1992
24. Roca A, Sullivan W, Blackmon D, Lebow J, Koopman WJ, **Moreland L**: Evaluating the rehabilitation of arthritis patients using the functional independence measure. *Arthritis Rheum (Suppl)* 35:R8, 1992
25. Garver RI Jr, **Moreland LW**, Goldsmith KT, Young KR Jr: Changes in amounts of transforming growth factor within fibrotic scleroderma lungs. *Clinical Research* 40:261A, 1992
26. **Moreland LW**, Pratt PW, Bucy P, Jackson B, Feldman J, Koopman WJ: Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti-CD<sub>4</sub> antibody. *Arthritis Rheum (Suppl)* 35:S44, 1992; *Clinical Research* 40:845A, 1992
27. Pratt PW, Bucy RP, **Moreland LW**, Koopman WJ: Thymic processing appears to contribute to repopulation of CD<sub>4</sub> lymphocytes after depletion with chimeric CD<sub>4</sub> antibody in refractory rheumatoid arthritis. *Arthritis Rheum (Suppl)* 35:S105, 1992
28. **Moreland LW**, Goldsmith K, Russell WJ, Young KR, Jr., Garver RI, Jr: Transforming growth factor  $\beta$  within fibrotic scleroderma lungs. *Arthritis Rheum (Suppl)* 35:S204, 1992
29. Huff JP, Sequeira W, Harris C, Blackburn WD, **Moreland LW**: Survey of physicians doing office-based arthroscopy. *Arthritis Rheum (Suppl)* 35:S292, 1992
30. **Moreland LW**, Sewell KL, Sullivan WF, Shmerlings RH, Parker KC, Swartz WG, Woodworth TG, Koopman WJ, Trentham DE: Treatment of refractory rheumatoid arthritis with DAB<sub>486</sub> IL-2 fusion toxin: Double-blind, placebo-controlled study. *Clinical Research* 41:245A, 1993; *Arthritis Rheum (Suppl)* 36:R24, 1993
31. Jackson B, Pratt PW, **Moreland LW**, Alarcón GS: Outcome measurements in rheumatoid arthritis clinical trials (OMERACT): Use of Boston and Maastricht criteria in a group of patients from the phase I anti-chimeric CD<sub>4</sub> antibody trial. *Arthritis Rheum (Suppl)* 36:R21, 1993
32. **Moreland LW**, Arnold WJ, Saway A, Savory C, Sikes D: Efficacy and safety of intra-articular Hylan GF20 (Synvisc), A viscoelastic derivative of hyaluronan in patients with osteoarthritis of the knee. *Arthritis Rheum (Suppl)* 36:S165, 1993
33. **Moreland LW**, Sewell KL, Sullivan WF, Shmerling RH, Parker KC, Swartz WG, Woodworth TG, Trentham DE, Koopman WJ: Double-blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB<sub>486</sub> IL-2) in patients with refractory rheumatoid arthritis (RA). *Arthritis Rheum (Suppl)* 36:S39, 1993
34. **Moreland LW**, Pratt PW, Mayes M, Postlethwaite A, Weisman M, Schnitzer T, Lightfoot R, Calabrese L, Koopman W: Minimal efficacy of a depleting chimeric anti-CD<sub>4</sub> (CM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX). *Arthritis Rheum (Suppl)* 36:S39, 1993
35. Bucy RP, **Moreland LW**, Dion D, Li J, Qiang Huang G, Koopman WJ: Immunohistologic studies of rheumatoid arthritis (RA) synovial tissue obtained using outpatient arthroscopy in patients receiving DAB<sub>486</sub> IL-2 compared to untreated early RA patients. *Arthritis Rheum (Suppl)* 36:S128, 1993
36. **Moreland LW**, Bucy RP, Jackson B, Feldman J, Koopman WJ: Long-term follow-up (30 months) of rheumatoid arthritis patients treated with a chimeric anti-CD<sub>4</sub> monoclonal antibody (cMAB). *Arthritis Rheum (Suppl)* 36:S129, 1993
37. Schrohenloher RE, Koopman WJ, Woodworth TG, **Moreland LW**: Suppression of *in vitro* IgM and IgM rheumatoid factor production by DAB<sub>486</sub> IL-2 fusion toxin therapy in rheumatoid arthritis (RA). *Arthritis Rheum (Suppl)* 36:S130, 1993

38. Sewell KL, **Moreland LW**, Cush JJ, Furst DE, Woodworth TG, Meehan RT: Phase I/II double-blind, dose-response trial of a second fusion toxin, DAB<sub>389</sub> IL-2, in rheumatoid arthritis. *Arthritis Rheum (Suppl)* 36:S130, 1993
39. Alarcón GS, Jackson B, Parkhill TR, **Moreland LW**, Woodworth T, Koopman WJ: Performance of the MAASTRICH criteria compared with clinical response criteria used in the phase II DAB<sub>486</sub> IL-2 fusion toxin trial in the treatment of rheumatoid arthritis. *Arthritis Rheum (Suppl)* 36:S179, 1993
40. Furst DE, Parker K, **Moreland LW**, Woodworth T: Variations in swollen joint counts during DMARD wash-outs and placebo treatment in patients entering DAB IL-2 trials. *Arthritis Rheum (Suppl)* 36:S179, 1993
41. **Moreland LW**, Saway PA, Jacobs C, Beck C, Bloesch C, Koopman WJ: Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis. *Clinical Research* 42:312A, 1994
42. **Moreland LW**, Heck LW, Koopman WJ, Saway PA, Adamson TC, Fronck Z, O'Connor RD, Morgan EZ, Brostoff SW: Vβ17 T-cell receptor peptide vaccine: results of a phase I dose-finding study in patients with rheumatoid arthritis. *Arthritis Rheum (Suppl)* 37:R28, 1994; *Arthritis Rheum (Suppl)* 37:S337, 1994; and *Clinical Research* 42:312A, 1994
43. **Moreland LW**, Margolies GR, Heck, LW, Saway PA, Jacobs C, Beck C, Bloesch C, Koopman WJ: Soluble tumor necrosis factor receptor (sTNFR): results of a phase I dose-escalation study in patients with rheumatoid arthritis. *Arthritis Rheum (Suppl)* 37:R27, 1994; *Arthritis Rheum (Suppl)* 37:S295, 1994; and *Clinical Research* 42:312A, 1994
44. **Moreland LW**, Calvo-Alén J, Koopman WJ: Outpatient knee arthroscopy: a safe method to obtain synovial tissue. *Arthritis Rheum (Suppl)* 37:R25, 1994
45. Clements PJ, Lachenbruch PA, Seibold IR, Furst DE, for the Investigators in the High-Dose vs Low-Dose Penicillamine (D-Pen) in SSc Trial: Health Assessment Questionnaire (HAQ) in patients with early, diffuse cutaneous systemic sclerosis (SSc). *Arthritis Rheum (Suppl)* 37:S260, 1994
46. Klashman DJ, **Moreland LW**, Ike RW, Kalunian JC: Occult presence of CPPD crystals in patients undergoing arthroscopic knee irrigation for refractory knee pain related to OA. *Arthritis Rheum (Suppl)* 37:S240, 1994
47. Drevlow B, Lovis R, Haag MA, Sinacore J, Jacobs C, Bloesch C, Beck C, Landay A, **Moreland L**, Pope RM: Phase I study of recombinant human interleukin-1 receptor (RHU IL-1R) administered subcutaneously in patients with active rheumatoid arthritis. *Arthritis Rheum (Suppl)* 37:S339, 1994
48. Sewell KL, **Moreland LW**, Furst DE, Meehan RT, Kremer JM, Ribby WFC, Parker KC, Lynch AM, Woodworth TG: Phase II open-label trial of DAB<sub>389</sub> IL-2 administered up to four times a year to patients with active rheumatoid arthritis. *Arthritis Rheum (Suppl)* 37:S341, 1994
49. Rich E, Calvo-Alén J, Koopman WJ, Kalunian KC, **Moreland LW**: Synovial biopsy by needle arthroscopy: a useful research tool. *J Investigative Medicine (Suppl)* 43:362A, 1995, *Arthritis Rheum (Suppl)* (in press)
50. Gay RM Jr, **Moreland LW**, Koopman WJ, Bucy RP: Immunohistologic studies of early rheumatoid arthritis synovial tissue obtained by arthroscopy. *J Investigative Medicine (Suppl)* 43:362A, 1995, *Arthritis Rheum (Suppl)* (in press)
51. **Moreland LW**, Bucy RP, Knowles RW, Wacholtz MC, Haverty TP, Koopman WJ: Treating rheumatoid arthritis with a non-depleting anti-CD<sub>4</sub> monoclonal antibody (MAb). *J Investigative Medicine (Suppl)* 43:362A, 1995, *Arthritis Rheum (Suppl)* (in press)

52. Rich E, **Moreland LW**, Alarcón GS, Hook EW: Point prevalence of reactive arthritis (ReA) in a large urban sexually transmitted disease (STD) clinic. Arthritis Rheum (Suppl) (in press)

**Poster Exhibits:**

1. **Moreland L**, McKenzie R, Brick J: Temporal arteritis presenting as sixth nerve palsy. National American College of Physicians Meeting, March, 1985, Washington, DC
2. **Moreland L**, DiBartolomeo A, Riley R: Polyarteritis nodosa presenting as a renal mass in a patient with rheumatoid arthritis. Regional American College of Physicians Meeting - October, 1985, Morgantown, WV
3. **Moreland L**, DiBartolomeo A, Riley R: A patient with rheumatoid arthritis and a renal mass. National American College of Physicians Meeting - April 1986, San Francisco, CA
4. Brick JE, **Moreland LW**, DiBartolomeo AG: Outcome analysis of selected methotrexate (MTX) treated rheumatoid arthritis (RA) patients. Southeastern Regional American Rheumatism Association Meeting, December, 1987, Nashville, TN
5. **Moreland L**, Huang GQ, Gay R, Stewart T, Gay S: Immunohistological demonstration of collagen type II in synovial fluid phagocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Fourth Annual Trainee Research Symposium; University of Alabama at Birmingham, Department of Medicine, March, 1988
6. **Moreland LW**, López-Méndez A, Alarcón GS: Spinal stenosis (SPST) as seen by rheumatologists (R) in a university-based rheumatology practice. Regional American Rheumatism Association Meeting, Tampa, FL, November, 1988
7. Stewart TE, Mestecky J, **Moreland LW**, Gay S: Immunoassay for collagen type II (CII) in synovial fluid and serum of patients with erosive joint diseases. Regional American Rheumatism Association Meeting, Tampa, FL, November, 1988
8. **Moreland LW**, McGee N, Huang G, Stewart T, Gay S: Immunoelectron microscopy (IEM) of collagen type II (CII) in synovial fluid phagocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Regional American Rheumatism Association Meeting, Tampa, FL, November, 1988
9. Alarcón GS, **Moreland LW**, Ambrose RE, Kendall Jr LG, Brown Jr S: Theory vs practice in the development and validation of a methotrexate (MTX) algorithm (ALGO) for rheumatoid arthritis (RA). Regional American Rheumatism Association Meeting, Tampa, FL, November, 1988; National American College of Rheumatology Meeting, Cincinnati, Ohio, June 1989
10. Chatham WW, Williams GV, **Moreland LW**, Parker JW, Ross C, Alarcón GS: Intraarticular (IA) injections: should we rest the joints (JTS)? Regional American Rheumatism Association Meeting, Tampa, FL, November, 1988
11. **Moreland L**, Stewart T, Gay RE, Gay S: Autoantibodies to collagen types I-VI in vasculitis and systemic lupus erythematosus. Fifth Annual Trainee Research Symposium; The University of Alabama at Birmingham, Department of Medicine, February, 1989; National American College of Rheumatology Meeting, Cincinnati, Ohio, June 1989
12. Joy JL, López-Méndez A, **Moreland LW**, Alarcón GS, Oh SH: Electrophysiologic findings in patients with radiologically proven spinal stenosis. The American Association of Electromyography and Electrodiagnosis. Washington, D.C., September, 1989
13. **Moreland LW**, Daniel WW, Alarcón GS: The value of the Norgaard view (NV) in the evaluation of erosive arthritis. April, 1990, Southeastern Regional American College of Rheumatology Meeting, Richmond, VA, April, 1990

14. Ambrose RF, Brown S, **Moreland LW**, Alarcón GS: Constructing clinical algorithms for arthritis education: an eight step process. Southeastern Regional American College of Rheumatology Meeting, Richmond, VA, April, 1990
15. **Moreland LW**, Huang G, Gay RE, Jones RE, Blackburn WD, Alarcón GS, Gay S: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in scleroderma (SCL) skin. Southeastern Regional American College of Rheumatology Meeting, Richmond, VA, April, 1990; Sixth Annual Trainee Research Symposium, Department of Medicine, The University of Alabama at Birmingham, February, 1990
16. Stransky G, **Moreland LW**, Gay RE, Gay S: Virus-like particles (VLP) in synovial fluids from patients with rheumatoid arthritis (RA). National American College of Rheumatology Meeting, Seattle, WA, October, 1990
17. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Ghrayeb J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Treatment of refractory rheumatoid arthritis (RA) with a chimeric anti-CD<sub>4</sub> monoclonal antibody. Presented at conference on Molecular Biology and the Immunopathogenesis of Rheumatoid Arthritis, Lake Tahoe, February, 1991
18. **Moreland LW**, Reddy MS, Koopman WJ, Sawyer MS, Bowden JC, Jeffcoat MK: Detection of erosive changes in rheumatoid arthritis (RA) using digital image subtraction radiography (DISR). Southeast Regional Meeting, American College of Rheumatology, Baltimore, MD, April, 1991
19. Pratt PW, **Moreland LW**, Barker JS, Snider AM, Alarcón GS: Routine bacteriologic studies in synovial fluid (SF) from inflamed joints in rheumatoid arthritis (RA) patients: a reassessment. Southeast Regional Meeting, American College of Rheumatology, Baltimore, MD, April, 1991
20. Reddy MS, Jeffcoat MK, **Moreland LW**, Koopman WJ, Webber R: Digital subtraction radiography for the assessment of bone change in rheumatoid arthritis (RA). National American College of Rheumatology Meeting, Boston, MA, November, 1991
21. Pratt PW, Bucy RP, **Moreland LW**, Koopman WJ: Thymic processing appears to contribute to repopulation of CD<sub>4</sub> lymphocytes after depletion with chimeric CD<sub>4</sub> antibody in refractory rheumatoid arthritis. Eighth Annual Trainee Research Symposium, Department of Medicine, The University of Alabama at Birmingham, February, 1992
22. Brown DA, **Moreland LW**, Alarcón GS: Practice variations in the administration of gold salts (GS) for the treatment of rheumatoid arthritis (RA) during a ten year period. 28th Annual Medical Student Research Day; University of Alabama at Birmingham. Presented at the Southeast Regional American College of Rheumatology Meeting, New Orleans, LA, March, 1992. Presented at the 1992 National American College of Rheumatology Meeting, October, 1992, Atlanta, GA
23. Roca A, Sullivan W, Blackmon D, Lebow J, Koopman WJ, **Moreland L**: Evaluating the rehabilitation of arthritis patients using the functional independence measure. Southeast Regional American College of Rheumatology Meeting, New Orleans, LA, March, 1992
24. Garver RI Jr, **Moreland LW**, Goldsmith KT, Young KR Jr: Changes in amounts of transforming growth factor within fibrotic scleroderma lungs. Presented at 1992 National American Federation for Clinical Research Meeting, Washington, DC, May, 1992
25. **Moreland LW**, Pratt PW, Bucy P, Jackson B, Feldman J, Koopman WJ: Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti-CD<sub>4</sub> antibody. Presented at 1992 National American College of Rheumatology Meeting, Atlanta, GA, October, 1992

26. Pratt PW, Bucy RP, **Moreland LW**, Koopman WJ: Thymic processing appears to contribute to repopulation of CD<sub>4</sub> lymphocytes after depletion with chimeric CD<sub>4</sub> antibody in refractory rheumatoid arthritis. Presented at 1992 National American College of Rheumatology Meeting, Atlanta, GA, October, 1992
27. **Moreland LW**, Goldsmith K, Russell WJ, Young KR, Jr., Garver RI, Jr: Transforming growth factor  $\beta$  within fibrotic scleroderma lungs. Presented at 1992 National American College of Rheumatology Meeting, Atlanta, GA, October, 1992
28. Blackmon D, Sullivan W, Roca A, Lebow J, Koopman WJ, **Moreland LW**: Efficacy of rehabilitation in rheumatoid arthritis patients assessed by the Functional Independence Measure (FIM). Presented at the 1992 National Arthritis Health Professions Association Meeting, Atlanta, GA, October, 1992
29. Sullivan, WF, **Moreland LW**, Sewell KL, Shmerling RH, Parker KC, Swartz WG, Woodworth TG, Koopman WJ, Trentham DE: Treatment of refractory rheumatoid arthritis with DAB<sub>(486)</sub> IL-2 fusion toxin: double blind, placebo controlled study. Ninth Annual Trainee Research Symposium, Department of Medicine, The University of Alabama at Birmingham, February, 1993
30. **Moreland LW**, Sewell KL, Sullivan WF, Shmerlings RH, Parker KC, Swartz WG, Woodworth TG, Koopman WJ, Trentham DE: Treatment of refractory rheumatoid arthritis with DAB<sub>486</sub> IL-2 fusion toxin: Double-blind, placebo-controlled study. Presented at the 1993 National American Society Clinical Research Meeting, Washington, DC, April, 1993, Presented at the Southeastern Regional American College of Rheumatology Meeting, Arlington, VA, April, 1993
31. Jackson B, Pratt PW, **Moreland LW**, Alarcón GS: Outcome measurements in rheumatoid arthritis clinical trials (OMERACT): Use of Boston and Maastricht criteria in a group of patients from the phase I anti-chimeric CD<sub>4</sub> antibody trial. Southeastern Regional American College of Rheumatology Meeting, Arlington, VA, April, 1993
32. **Moreland LW**, Arnold WJ, Saway A, Savory C, Sikes D: Efficacy and safety of intra-articular Hylan GF20 (Synvisc), A viscoelastic derivative of hyaluronan in patients with osteoarthritis of the knee. Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
33. Bucy RP, **Moreland LW**, Dion D, Li J, Qiang Huang G, Koopman WJ: Immunohistologic studies of rheumatoid arthritis (RA) synovial tissue obtained using outpatient arthroscopy in patients receiving DAB<sub>486</sub> IL-2 compared to untreated early RA patients. Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
34. **Moreland LW**, Bucy RP, Jackson B, Feldman J, Koopman WJ: Long-term follow-up (30 months) of rheumatoid arthritis patients treated with a chimeric anti-CD<sub>4</sub> monoclonal antibody (cMAB). Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
35. Schrohenloher RE, Koopman WJ, Woodworth TG, **Moreland LW**: Suppression of *in vitro* IgM and IgM rheumatoid factor production by DAB<sub>486</sub> IL-2 fusion toxin therapy in rheumatoid arthritis (RA). Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
36. Sewell KL, **Moreland LW**, Cush JJ, Furst DE, Woodworth TG, Meehan RT: Phase I/II double-blind, dose-response trial of a second fusion toxin, DAB<sub>389</sub> IL-2, in rheumatoid arthritis. Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993

37. Alarcón GS, Jackson B, Parkhill TR, **Moreland LW**, Woodworth T, Koopman WJ: Performance of the MAASTRICH criteria compared with clinical response criteria used in the phase II DAB<sub>486</sub> IL-2 fusion toxin trial in the treatment of rheumatoid arthritis. Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
38. Furst DE, Parker K, **Moreland LW**, Woodworth T: Variations in swollen joint counts during DMARD wash-outs and placebo treatment in patients entering DAB IL-2 trials. Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
39. **Moreland LW**, Sullivan WF, Koopman WJ: Double-blind placebo-controlled phase II trial of Diphtheria-interleukin-2 fusion toxin (DAB<sub>486</sub> IL-2) in patients with refractory rheumatoid arthritis (RA). NIH Annual General Clinical Research Center Meeting, Reston, VA, December, 1993
40. Margolies GR, Saway PA, Heck LW, Horton DW, Parkhill TR, Koopman WJ, **Moreland LW**: Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-evaluation study in patients with rheumatoid arthritis. Presented at the 10th Annual Trainee Research Symposium, Department of Medicine, The University of Alabama at Birmingham, February, 1994
41. **Moreland LW**, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Franek Z, O'Connor RD, Morgan EE, Brostoff SW: VB117 T-cell receptor peptide vaccine: Results of a phase I dose finding study in patients with rheumatoid arthritis. 1994 American Federation of Clinical Research Meeting, Baltimore, MD, April 29-May 2, 1994; 1994 Southeastern Regional American College of Rheumatology Meeting, May 13-15, 1994, Orlando, FL; 1994 National American College of Rheumatology Meeting, Minneapolis, MN, October 1994
42. **Moreland LW**, Saway PA, Jacobs C, Beck C, Blosch C, Koopman WJ: Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis. 1994 American Federation of Clinical Research Meeting, Baltimore, MD, April 29-May 2, 1994 and 1994 Southeastern Regional American College of Rheumatology Meeting, May 13-15, 1994, Orlando, FL
43. **Moreland LW**, Calvo-Alên J, Koopman WJ: Outpatient knee arthroscopy: a safe method to obtain synovial tissue. 1994 Southeastern Regional American College of Rheumatology Meeting, May 13-15, 1994, Orlando, FL
44. Clements PJ, Lachenbruch PA, Seibold JR, Furst DE, for the Investigators in the High-Dose versus Low-Dose Penicillamine (D-Pen) in SSc Trial: Health Assessment Questionnaire (HAQ) in patients with early, diffuse cutaneous systemic sclerosis (SSc). Presented at the 1994 National American College of Rheumatology Meeting, Minneapolis, MN, October, 1994
45. Klashman DJ, **Moreland LW**, Ike RW, Kalunian KC: Occult presence of CPPD crystals in patients undergoing arthroscopic knee irrigation for refractory knee pain related to OA. Presented at the 1994 National American College of Rheumatology Meeting, Minneapolis, MN, October, 1994
46. Drevlon B, Louis R, Haag MA, Sinacore J, Jacobs C, Blosch C, Beck C, Landay A, **Moreland L**, Pope RM: Phase I study of recombinant human interleukin-1 receptor (RHU IL-1R) administered subcutaneously in patients with active rheumatoid arthritis. Presented at the 1994 National American College of Rheumatology Meeting, Minneapolis, MN, October, 1994

47. Sewell KL, **Moreland LW**, Furst DE, Meehan RT, Kremer JM, Rigby WFC, Parker KC, Lynch AM, Woodworth TG: Phase II open-label trial of DAB<sub>389</sub> IL-2 administered up to four times a year to patients with active rheumatoid arthritis. Presented at the 1994 National American College of Rheumatology Meeting, Minneapolis, MN, October, 1994
48. Rich E, Calvo-Alén J, Koopman WJ, Kalunian KC, **Moreland LW**: Synovial biopsy needle arthroscopy: a useful research tool. Clinical Research Meeting, San Diego, CA, May 5-8, 1995; Southeastern Regional American College of Rheumatology Meeting, Philadelphia, PA, April 28-30, 1995
49. Gay RM Jr, **Moreland LW**, Koopman WJ, Bucy RP: Immunohistologic studies of early rheumatoid arthritis synovial tissue obtained by arthroscopy. Clinical Research Meeting, San Diego, CA, May 5-8, 1995; Southeastern Regional American College of Rheumatology Meeting, Philadelphia, PA, April 28-30, 1995
50. **Moreland LW**, Bucy RP, Knowles RW, Wacholtz MC, Haverty TP, Koopman WJ: Treating rheumatoid arthritis with a nondepleting anti-CD<sub>4</sub> monoclonal antibody (MAb). NIH Annual Clinical Research Meeting, San Diego, CA, May 5-8, 1995; Southeastern Regional American College of Rheumatology Meeting, Philadelphia, PA, April 28-30, 1995

### Oral Presentations:

### Scientific papers presented at national and international meetings

1. **Moreland L**, Huang GQ, Gay R, Stewart T, Gay S: Immunohistological demonstration of collagen type II in synovial fluid phagocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. National American Rheumatism Association Meeting, Houston, Texas, May, 1988
2. Brick J, **Moreland L**, Al-Kawas F, Chang W, DiBartolomeo A: Prospective analysis of pre and post methotrexate (MTX) liver biopsies (Bx) in rheumatoid arthritis (RA) patients. National American Rheumatism Association Meeting, Houston, Texas, May 1988
3. Stewart TE, Mestecky J, **Moreland LW**, Gay S: Immunoassay for collagen type II (CII) in synovial fluid and serum of patients with erosive joint diseases. National American College of Rheumatology Meeting, Cincinnati, Ohio, June, 1989
4. **Moreland L**, Stewart T, Gay RE, Gay S: Autoantibodies to collagen types I-VI in vasculitis and systemic lupus erythematosus. National American College of Rheumatology Meeting, Cincinnati, Ohio, June, 1989
5. **Moreland LW**, Stewart TE, Gay RE, Huang G, Gay S: Collagen type II in serum, synovial fluid and synovial phagocytes as a marker of cartilage destruction. XVIIth ILAR Congress of Rheumatology, Rio de Janeiro, Brazil, September, 1989
6. **Moreland LW**, Huang G, Gay RE, Jones RE, Blackburn WD, Alarcón GS, Gay S: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in scleroderma (SCL) skin. National American College of Rheumatology Meeting, Seattle, WA, October, 1990
7. **Moreland LW**: The evaluation of cartilage and synovial changes in OA of the knee with the treatment of flurbiprofen using an optical catheter system arthroscope. Presented in Sanoma, California symposium on "The effects of flurbiprofen on the immune response." September, 1990
8. **Moreland LW**, Koopman WJ: Chimeric anti-CD<sub>4</sub> in treating rheumatoid arthritis. European Concerted Action on Immunopathogenesis and Immunotherapy of Rheumatoid Arthritis (2nd Annual Meeting), Schlob Elmau, Bavarian Alps, April 21-24, 1991

9. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Ghrayeb J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Treatment of refractory rheumatoid arthritis (RA) with a chimeric anti-CD<sub>4</sub> monoclonal antibody. Presented at National American Federation of Clinical Research Meeting, Seattle, May, 1991
10. **Moreland LW**, Stromatt SC, Tindall E, Brown J: Efficacy of misoprostol in the prevention of nonsteroidal anti-inflammatory drug-induced duodenal ulcers. XIIth European Congress of Rheumatology, Budapest, Hungary, June 30-July 6, 1991
11. Reddy MS, Jeffcoat MK, **Moreland LW**, Koopman WJ, Webber R: Digital subtraction radiography for the assessment of bone change in rheumatoid arthritis (RA). National American College of Rheumatology Meeting, Boston, MA, November, 1991
12. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Ghrayeb J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Use of a chimeric anti-CD<sub>4</sub> monoclonal antibody in refractory rheumatoid arthritis. National American College of Rheumatology Meeting, Boston, MA, November, 1991
13. **Moreland LW**, Reddy MS, Koopman WJ, Jeffcoat MK: Digital imaging subtraction radiography (DISR) for detection of erosive changes in hands of rheumatoid arthritis (RA) patients treated with Flurbiprofen (FLU). International Congress of Inflammation Meeting, Rome Italy, October 6-11, 1992
14. **Moreland LW**, Bucy RP, Pratt PW, Khazaeli MB, LoBuglio AF, Gh J, Daddona P, Sanders ME, Kilgariff C, Riethmüller G, Koopman WJ: Use of a chimeric anti-CD<sub>4</sub> monoclonal antibody in refractory rheumatoid arthritis. International Congress of Inflammation Meeting, Rome, Italy, October 6-11, 1992
15. **Moreland LW**, Pratt PW, Bucy P, Jackson B, Feldman J, Koopman WJ: Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti-CD<sub>4</sub> antibody. Presented at 1992 National American College of Rheumatology Meeting, Atlanta, GA, October, 1992; Presented at the Southern Section American Federation for Clinical Research, New Orleans, LA, January 23, 1993
16. **Moreland LW**, Sanders M, Pratt W, Koopman WJ: Experience with a chimeric monoclonal anti-CD<sub>4</sub> antibody in the treatment of refractory rheumatoid arthritis. The Second International Symposium on the Immunotherapy of Rheumatic Diseases, Brighton, England, April 1-4, 1993
17. **Moreland LW**, Sewell KL, Sullivan WF, Shmerling RH, Parker KC, Swartz WG, Woodworth TG, Trentham DE, Koopman WJ: Double-blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB<sub>486</sub> IL-2) in patients with refractory rheumatoid arthritis (RA). Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
18. **Moreland LW**, Pratt PW, Mayes M, Postlethwaite A, Weisman M, Schnitzer T, Lightfoot R, Calabrese L, Koopman W: Minimal efficacy of a depleting chimeric anti-CD<sub>4</sub> (CM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX). Presented at the 57th American College of Rheumatology Annual Meeting, San Antonio, Texas, November, 1993
19. **Moreland LW**, Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C Bosch C, Koopman WJ: Soluble tumor necrosis factor receptor (STNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis. Presented at the 58th American College of Rheumatology Annual Meeting, Minneapolis, MN, October, 1994
20. **Moreland LW**: Hylan GF-20 in treating osteoarthritis. International Business Communications Meeting: Osteoarthritis; Advances in Pathobiology, diagnosis and treatment. December 1, 1994, Washington, DC



21. **Moreland LW:** Potential new therapies for rheumatoid arthritis: anti-CD<sub>4</sub>, TNFR: Fc receptor. International Business Communications Meeting: Rheumatoid Arthritis; Advances in Pathobiology, diagnosis and treatment. December 1, 1994, Washington, DC

**Scientific papers presented at local and regional meetings**

1. **Moreland LW, Brick JE, Kovach RF, DiBartolomeo AG, Mullins MC:** Musculoskeletal manifestations of acute febrile neutrophilic dermatosis (Sweet's syndrome). Southeastern Regional American Rheumatism Association Meeting, December, 1987, Nashville, TN
2. **Brick JE, Moreland LW, Al-Kawas F, Chang WWL, DiBartolomeo AG:** Prospective analysis of pre and post methotrexate (MTX) liver biopsies (Bx) in rheumatoid arthritis (RA) patients. Southeastern Regional American Rheumatism Association Meeting, December, 1987, Nashville, TN
3. **Moreland LW, Ray RE, Gay S:** Immunological detection of collagen type II in patients with rheumatoid arthritis and osteoarthritis. Presented at Southern Section, American Federation for Clinical Research Meeting, January, 1991, New Orleans
4. **Moreland LW, Pratt PW, Bucy P, Jackson B, Feldman J, Koopman WJ:** Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti-CD<sub>4</sub> antibody. Presented at Southern Section, American Federation for Clinical Research Meeting, New Orleans, LA, January 23, 1993
5. **Rich E, Moreland LW, Alarcón GS, Hook EW:** Point prevalence of reactive arthritis (ReA) in a large urban sexually transmitted disease (STD) clinic. Southeast Regional American College of Rheumatology Meeting, Philadelphia, PA, April 28-3, 1995

**Invited Lectures at Local and Regional Courses and Meetings**

Baptist Montclair Family Practice Weekly Conference, March 9, 1989; "NSAID- Induced Gastropathy"

Aching Bones Conference, UAB, April 25, 1989; "Seronegative Spondyloarthropathies"

Medical Center East Weekly Family Practice Conference, April 25, 1989; "NSAID - Induced Gastropathy"

UAB Family Practice Weekly Conference, May 16, 1989; "Systemic Lupus Erythematosus and Mixed Connective Tissue Disease"

Fox Army Hospital, Huntsville, AL; July 12, 1989; "Osteoarthritis: Current Concepts and New Treatments"

University of Alabama Hospital Family Practice Center, Huntsville, AL, July 13, 1989; "Osteoarthritis: Current Concepts and New Treatments"

Scleroderma Patient Education Update, UAB, November 4, 1989; "Current Treatments of Scleroderma"

Golden Triangle Regional Medical Center, Columbus, MS, January 26, 1990; "New Perspectives in the Treatment of Rheumatoid Arthritis"

Baptist Medical Center Princeton, Medicine Conference, February 13, 1990; "Seronegative Spondyloarthropathies"

Oktibbeha County Medical Society, Starkville, MS, February 22, 1990; "New Perspectives in the Treatment of Rheumatoid Arthritis"

University of South Alabama, Department of Medicine Weekly Conference, March 20, 1990; "Nonsteroidal Anti-inflammatory Drugs and the Gastrointestinal Tract"

Carraway Methodist Hospital Medical Center, Medical Grand Round Conference, March 27, 1990; "Current and New Therapies for Rheumatoid Arthritis"

The University of Alabama at Huntsville, Internal Medicine Conference, October 18, 1990; "Bone Remodeling in Arthritis"

Selma Family Medicine Center, Weekly Conference, October 22, 1990; "New Perspectives in Arthritis Treatment"

Carraway Methodist Hospital Medical Center, Weekly Teaching Conference, December 4, 1990; "New Concepts in the Treatment of Rheumatoid Arthritis"

Naples Family Practice Conference, Naples, FL, January 22, 1991; "New Perspectives in the Treatment of Rheumatoid Arthritis"

Baptist Medical Center Princeton, Medicine Conference, June 4, 1991; "Osteoarthritis"

Alabama State Medical Association Annual Meeting, Birmingham, AL, June 22, 1991; "Update on Management of Arthritis"

Schumpert Medical Center, Medicine Conference, Shreveport, LA, July 24, 1991; "Clinical Perspectives in Rheumatoid Arthritis"

Etowah County Medical Society, Gadsden, AL, October 17, 1991; "The Medical Management of the Arthritis Patient"

Baptist Medical Center Princeton, Medical Conference, November 12, 1991; "Rheumatoid Arthritis Update and Treatment"

East Mississippi Medical Society, Meridian, MS, December 3, 1991; "New Perspectives in the Treatment of Rheumatoid Arthritis"

Ft. McClellan Nobel Army Hospital, January 1, 1992; "Current and New Treatments for Rheumatoid Arthritis"

Education Update for Scleroderma Patients, UAB, January 25, 1992; "Musculoskeletal Manifestations of Scleroderma"

South Highlands Hospital, Birmingham, AL, Medicine Conference, February 2, 1992; "Current Treatment of Rheumatoid Arthritis"

Baptist Montclair, Family Practice Conference, March 2, 1992, "Treatment of Rheumatoid Arthritis"

Community Medical Arts Group, Monthly Medical Lecture, Alexander City, AL, April 7, 1992; "Treatment for Rheumatoid Arthritis"

Tennessee Academy of Family Physicians Annual Seminar, Nashville, TN, April 10, 1992; "Current and New Treatments for Rheumatoid Arthritis"

Morgan County Medical Society, Decatur, AL, June 2, 1992; "Research in Rheumatoid Arthritis"

Georgia Podiatry Medical Association Summer Meeting, July 10, 1992; "Detection of Erosive Changes in Rheumatoid Arthritis"

Veterans Administration Weekly Grand Rounds Talk, Tuscaloosa, AL, July 21, 1992; "Current and New Treatments for Rheumatoid Arthritis"

Alabama Society of Physician Assistants, The University of Alabama at Birmingham, October 10, 1992; "Osteoarthritis: Current Therapeutic Options"

Arthritis Foundation Northeastern Ohio Chapter, Canton, Ohio; October 21, 1992; "Current Perspectives in Treating Rheumatoid Arthritis"

Carraway Methodist Hospital Medical Center, Medicine Grand Rounds, March 23, 1993; "Review of Scleroderma"

Family Medicine Conference, Selma, AL, May 20, 1993; "Current and New Therapies for Rheumatoid Arthritis"

Decatur Internal Medicine Monthly Conference, Decatur AL, September 7, 1993; "Treatment of Rheumatoid Arthritis"

1993 Arthritis Update, Division of Clinical Immunology and Rheumatology, UAB, Elmore County, September 9, 1993; "Update on Arthritis"

Carraway Methodist Hospital, Internal Medicine Conference, February 22, 1994; "Scleroderma Update"

Gastroenterology Update 1994, The University of Alabama at Birmingham, April 15, 1994; "NSAID's and Gastroduodenal Ulcer Disease: Treatment and Prevention"

American College of Physicians Board Review Course, The University of Alabama at Birmingham, May, 1994; Rheumatology Lectures (shared with Dennis Boulware, MD)

UAB Department of Medicine Residents Conference, June 17, 1994; "Vasculitis"

Lloyd Noland Hospital, Birmingham, Alabama, Medicine Grand Rounds, June 28, 1994; "Vasculitis"

Auburn University School of Pharmacy CME Program: "Current and New Therapies for Rheumatoid Arthritis"; Gulf Shores, AL, August 5, 1994

Auburn University School of Pharmacy CME Program: "Current and New Therapies for Rheumatoid Arthritis"; Lake Guntersville, AL, August 12, 1994

12th Annual Rheumatology on the Beach, Sandestin, FL, September 22-25, 1994; "Cytokine Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis"

Baptist Medical Center Princeton, November 29, 1994; "Biologic Agents as Potential New Therapies for Autoimmune Disease"

Central Regional American College of Rheumatology, March 31, 1995; "Biologic Agents: Fact or Fiction"

Druid City Hospital Regional Medical Center, Tuscaloosa, Alabama: "Current Therapy for Rheumatoid Arthritis", April 14, 1995

UAB Department of Medicine Residents Conference, June 2, 1995; "Vasculitis"

## **MISCELLANEOUS**

### **Educational tapes and courses developed, etc.**

- Organizer, Scleroderma Patient Education Update, The University of Alabama at Birmingham, November, 1989
- "Outpatient Arthroscopy for the Rheumatologist" - Videotape, February 1991, Warren D. Blackburn, Jr., Larry W. Moreland
- Organizer, "Them Achin Bones" Conference for Health Care Professionals (May 8-9, 1991), UAB
- Organizer, Scleroderma Patient Education Update, The University of Alabama at Birmingham, January, 1992
- Organizer, "Current Topics in Arthritis", September 25, 1993, The University of Alabama at Birmingham Divisions of CME and Clinical Immunology and Rheumatology